Alligator Bioscience AB (publ)

BATS-CHIXE:ATORXS Stock Report

Market Cap: SEK 384.7m

Alligator Bioscience Past Earnings Performance

Past criteria checks 0/6

Alligator Bioscience's earnings have been declining at an average annual rate of -7%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 18.9% per year.

Key information

-7.0%

Earnings growth rate

10.7%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-18.9%
Return on equity-802.5%
Net Margin-526.2%
Next Earnings Update13 Jul 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Alligator Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:ATORXS Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2340-213720
31 Dec 2236-193690
30 Sep 2221-177650
30 Jun 2220-163630
31 Mar 2218-152590
31 Dec 2113-142570
30 Sep 218-139540
30 Jun 215-133510
31 Mar 216-133530
31 Dec 206-143560
30 Sep 205-169590
30 Jun 209-194620
31 Mar 204-209620
31 Dec 194-210610
30 Sep 1930-181600
30 Jun 1926-164580
31 Mar 1926-152550
31 Dec 1827-150520
30 Sep 1853-107540
30 Jun 1854-93510
31 Mar 1855-86480
31 Dec 1757-64440
30 Sep 1712-96400
30 Jun 1715-77370
31 Mar 1718-91350
31 Dec 1659-48330
30 Sep 1655-68310
31 Dec 15292207320
31 Dec 141-77310

Quality Earnings: ATORXS is currently unprofitable.

Growing Profit Margin: ATORXS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ATORXS is unprofitable, and losses have increased over the past 5 years at a rate of 7% per year.

Accelerating Growth: Unable to compare ATORXS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ATORXS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).


Return on Equity

High ROE: ATORXS has a negative Return on Equity (-802.5%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies